2022
DOI: 10.1111/jcpt.13759
|View full text |Cite
|
Sign up to set email alerts
|

Dynamic changes in the levels of sCD62L and SPARC in chronic myeloid leukaemia patients during imatinib treatment

Abstract: What Is Known and Objective: Chronic myeloid leukaemia (CML) microenvironment is responsible for resistance of leukaemic cells to tyrosine kinase inhibitor, altered adhesion, increased proliferation and leukaemic cells growth and survival through the secretion of many soluble molecules. We aimed at monitoring soluble L-selectin (sCD62L) and secreted protein acidic and rich in cysteine (SPARC) levels in chronic phase chronic myeloid leukaemia (CP-CML) patients and assessing the impact of imatinib on these param… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 41 publications
0
2
0
Order By: Relevance
“…Additionally, a shift in focus to maintaining long-term TFR stresses the need to eliminate MRD and the BCR::ABL1 + LSC in CML. Newer evidence sCD62L PB plasma Marker/putative predictor of response to TKI T-cell surface CD62L also interrelated with sCD62L and can predict responses [55,56]…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Additionally, a shift in focus to maintaining long-term TFR stresses the need to eliminate MRD and the BCR::ABL1 + LSC in CML. Newer evidence sCD62L PB plasma Marker/putative predictor of response to TKI T-cell surface CD62L also interrelated with sCD62L and can predict responses [55,56]…”
Section: Discussionmentioning
confidence: 99%
“…Previous reports suggested CML LSCs were more dependent on L-selectin (CD62L) for BM homing and disease engraftment [54]. Soluble CD62L is elevated in CP-CML patients and reduced following imatinib treatment [55], suggesting it may have value as a marker of treatment response. In addition, soluble and T cell expression of CD62L may predict responses to TKIs in CML [56], indicating this marker may be more related to T cell responses than the CML cells themselves.…”
Section: Adhesion Mechanismsmentioning
confidence: 98%